7 papers in the library · 13 citations · publishing 2022-2024
J Psychopharmacol April 23, 2024 Evan Cole Lewis, Alexandria Jaeger, Manesh Girn et al. 6 citations
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.
Journal of Psychoactive Drugs 2024 Reid Robison, Madeline Brendle, Claire Moore et al.
This study reports on 10 frontline healthcare workers, employed during the COVID-19 pandemic and experiencing symptoms of burnout and PTSD, treated with group ketamine-assisted psychotherapy (KAP) in a private outpatient clinic setting. Participants attended 6 sessions once weekly. These included 1 preparation session, 3 ketamine sessions (2 sublingual, 1 intramuscular), 2 integration sessions....
Brain Sciences February 2, 2023 Blerida Banushi, Madeline Brendle, Anya Ragnhildstveit et al.
Anxiety disorders are the most common group of mental disorders, but they are often underrecognized and undertreated in primary care. Dysfunctional breathing is a hallmark of anxiety disorders; however, mainstays of treatments do not tackle breathing in patients suffering anxiety. This scoping review aims to identify the nature and extent of the available research literature on the efficacy of...
Journal of Psychedelic Studies January 16, 2023 Madeline Brendle, Anya Ragnhildstveit, Matthew Slayton et al. 7 citations
Ketamine and esketamine have garnered interest in both psychiatric research and clinical practice for treatment-resistant depression (TRD). In this review, we examined registered trials investigating the therapeutic use of ketamine or esketamine for TRD, with the aim of characterizing emerging trends and knowledge gaps.The ClinicalTrials.gov electronic registry and results database was queried...
BMC Psychiatry October 3, 2022 S. Ahuja, M. Brendle, Leo Smart et al.
Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment and an evaluation of the real-world depression, anxiety, and safety outcomes...
Journal of Eating Disorders May 6, 2022 Reid Robison, Adele Lafrance, Madeline Brendle et al.
Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (ED) treatment were assessed. This study reports on five participants with a diagnosis of an ED and comorbid mood and anxiety disorders who received weekly...
Brain Sciences March 12, 2022 Anya Ragnhildstveit, Matthew Slayton, Laura Kate Jackson et al.
Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr)...